Analysts expect that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will announce ($0.61) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Global Blood Therapeutics’ earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.57). Global Blood Therapeutics posted earnings per share of ($0.58) in the same quarter last year, which indicates a negative year-over-year growth rate of 5.2%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Global Blood Therapeutics will report full-year earnings of ($2.42) per share for the current financial year, with EPS estimates ranging from ($2.78) to ($2.31). For the next financial year, analysts expect that the firm will report earnings of ($2.83) per share, with EPS estimates ranging from ($4.10) to ($2.25). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same period in the previous year, the firm posted ($0.58) EPS.
A number of research analysts recently issued reports on the company. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Cowen and Company restated an “outperform” rating and set a $83.00 price objective on shares of Global Blood Therapeutics in a research report on Monday, August 14th. J P Morgan Chase & Co restated an “overweight” rating and set a $46.00 price objective (up previously from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. ValuEngine upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Global Blood Therapeutics presently has an average rating of “Buy” and an average price target of $49.73.
Global Blood Therapeutics (NASDAQ GBT) traded down 4.89% on Friday, reaching $26.25. The company’s stock had a trading volume of 938,504 shares. The firm has a 50-day moving average price of $27.95 and a 200 day moving average price of $30.09. The firm’s market capitalization is $1.15 billion. Global Blood Therapeutics has a 52-week low of $13.35 and a 52-week high of $41.15.
In other news, Director Deval L. Patrick sold 27,053 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the sale, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 143,255 shares in the company, valued at approximately $4,297,650. The disclosure for this sale can be found here. Insiders have sold a total of 33,053 shares of company stock valued at $983,204 in the last quarter. 5.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley raised its stake in shares of Global Blood Therapeutics by 140.0% in the 1st quarter. Morgan Stanley now owns 334,872 shares of the company’s stock worth $12,340,000 after buying an additional 195,323 shares in the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Global Blood Therapeutics in the 2nd quarter worth $4,103,000. Creative Planning raised its stake in shares of Global Blood Therapeutics by 3,380.5% in the 2nd quarter. Creative Planning now owns 41,801 shares of the company’s stock worth $1,143,000 after buying an additional 40,600 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in shares of Global Blood Therapeutics in the 1st quarter worth $694,000. Finally, Vanguard Group Inc. raised its stake in shares of Global Blood Therapeutics by 40.1% in the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after buying an additional 726,366 shares in the last quarter. 86.07% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “-$0.61 EPS Expected for Global Blood Therapeutics, Inc. (GBT) This Quarter” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/09/12/0-61-eps-expected-for-global-blood-therapeutics-inc-gbt-this-quarter.html.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.